Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
1 "Jaehee Lee"
Article category
Publication year
Funded articles
Original Article
Article image
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea
Mi Kyung Kim, Jae-Han Jeon, Sung-Woo Kim, Jun Sung Moon, Nan Hee Cho, Eugene Han, Ji Hong You, Ji Yeon Lee, Miri Hyun, Jae Seok Park, Yong Shik Kwon, Yeon-Kyung Choi, Ki Tae Kwon, Shin Yup Lee, Eon Ju Jeon, Jin-Woo Kim, Hyo-Lim Hong, Hyun Hee Kwon, Chi Young Jung, Yin Young Lee, Eunyeoung Ha, Seung Min Chung, Jian Hur, June Hong Ahn, Na-young Kim, Shin-Woo Kim, Hyun Ha Chang, Yong Hoon Lee, Jaehee Lee, Keun-Gyu Park, Hyun Ah Kim, Ji-Hyun Lee
Diabetes Metab J. 2020;44(4):602-613.   Published online August 12, 2020
  • 13,967 View
  • 211 Download
  • 71 Web of Science
  • 81 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   

Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.


We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.


Compared with the non-DM group (n=847), patients with DM (n=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.


DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.


Citations to this article as recorded by  
  • Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
    Carmen Tisch, Eleni Xourgia, Aristomenis Exadaktylos, Mairi Ziaka
    Endocrine.2024;[Epub]     CrossRef
  • Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
    Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, Dorota Bednarska-Chabowska, Joanna Adamiec-Mroczek, Adrian Doroszko, Małgorzata Trocha, Krzysztof Kujawa, Agnieszka Matera-Witkiewicz, Edwin Kuźnik, Paweł Lubieniecki, Marcin Madziarski
    Biomedicines.2024; 12(3): 605.     CrossRef
  • Prognostic Value of Hyperglycemia and Insulin Resistance Among Patients with Confirmed COVID-19 Infections at Admission to the Alexandria Fever Hospital, Egypt
    Fathy Z. Alsewy, Magdy H. Megallaa, Salma A. Imbaby, Huda M. Zidan, Heba S. Kassab, Mai H. Badrah
    Metabolic Syndrome and Related Disorders.2024;[Epub]     CrossRef
  • The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
    Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
    Therapeutic Innovation & Regulatory Science.2024; 58(4): 773.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus
    D. V. Belikina, T. A. Nekrasova, L. G. Strongin, E. M. Durygina, M. Yu. Rodina
    FOCUS. Endocrinology.2024; 5(1): 20.     CrossRef
  • Research status and hotspots in the field of endoplasmic reticulum stress and liver disease: A bibliometric study
    Ruiyu Wang, Shu Huang, Ping Wang, Xiaowei Tang, Huan Xu, Wei Zhang, Lei Shi, Xiaolin Zhong, Muhan Lü, Xian Zhou, Xiaomin Shi
    Medicine.2024; 103(22): e38450.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2024; 11: 729.     CrossRef
  • Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
    Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
    Diabetes Research and Clinical Practice.2023; 195: 110205.     CrossRef
  • Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
    Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
    Diabetologia.2023; 66(8): 1395.     CrossRef
  • Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
    A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
    Obesity and metabolism.2023; 20(2): 92.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • Epidemiological features and consequences of COVID‐19 in patients with and without gastrointestinal symptoms in southwestern Iran. A retrospective observational study
    Habibollah Azarbakhsh, Leila Moftakhar, Aliasghar Valipour, Alireza Mirahmadizadeh, Hekmat Allah Moradi, Elahe Piraee
    Health Science Reports.2023;[Epub]     CrossRef
  • The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
    Yun-Ting Huang, Andrew Steptoe, Riyaz S. Patel, Esme Fuller Thomson, Dorina Cadar
    Gerontology.2023; 69(10): 1200.     CrossRef
  • Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
    Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
    Archives of Medical Research.2022; 53(2): 186.     CrossRef
  • Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
    Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
    Diabetes & Metabolism.2022; 48(1): 101307.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
    Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
    Primary Care Diabetes.2022; 16(1): 162.     CrossRef
  • Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
    Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
    Journal of Diabetes.2022; 14(2): 144.     CrossRef
  • Interplay between Inflammaging, Frailty and Nutrition in Covid-19: Preventive and Adjuvant Treatment Perspectives
    A. Padilha de Lima, M. Macedo Rogero, T. Araujo Viel, H.M. Garay-Malpartida, I. Aprahamian, Sandra Maria Lima Ribeiro
    The Journal of nutrition, health and aging.2022; 26(1): 67.     CrossRef
  • Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study
    Mi Seon Lee, Rosie Lee, Cheol Woo Ko, Jung Eun Moon
    Journal of Yeungnam Medical Science.2022; 39(1): 46.     CrossRef
  • Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
    Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, Huawei Jin
    Scientific Reports.2022;[Epub]     CrossRef
  • Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
    Afnan Alshnbari, Iskandar Idris
    Current Medical Research and Opinion.2022; 38(3): 357.     CrossRef
  • Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
    Li-Min Zhao, Xie-Hui Chen, Mei Qiu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • COVID-19 and Diabetes
    Awadhesh Kumar Singh, Kamlesh Khunti
    Annual Review of Medicine.2022; 73(1): 129.     CrossRef
  • The enzymes in COVID-19: A review
    Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior
    Biochimie.2022; 197: 38.     CrossRef
    Adnan A. Zainal, Marwan M. Merkhan
    Military Medical Science Letters.2022; 91(2): 140.     CrossRef
  • Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
    Adithan Ganesh, Michael D. Randall
    British Journal of Clinical Pharmacology.2022; 88(6): 2642.     CrossRef
  • Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
    Clifford J. Bailey, Mike Gwilt
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
    Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
    Frontiers in Clinical Diabetes and Healthcare.2022;[Epub]     CrossRef
  • Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
    Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
    Metabolism.2022; 131: 155196.     CrossRef
  • Glucose-Lowering Agents and COVID-19
    Ah Reum Khang
    The Journal of Korean Diabetes.2022; 23(1): 1.     CrossRef
  • Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
  • The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
    Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
    Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
    Journal of the American Heart Association.2022;[Epub]     CrossRef
  • Diabetes and SARS-CoV-2–Is There a Mutual Connection?
    Anna P. Jedrzejak, Edyta K. Urbaniak, Jadwiga A. Wasko, Natalia Ziojla, Malgorzata Borowiak
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
    Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
    F1000Research.2022; 11: 729.     CrossRef
  • Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?
    Marzieh Rohani-Rasaf, Kosar Mirjalili, Akram Vatannejad, Maryam Teimouri, Xiao-Feng Yang
    PLOS ONE.2022; 17(8): e0272000.     CrossRef
  • Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
    Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Annals of Medicine.2022; 54(1): 2724.     CrossRef
  • Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
    Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
    World Journal of Virology.2022; 11(6): 399.     CrossRef
  • Prevalencia de secuelas en pacientes con diabetes mellitus tipo 2 sobrevivientes al COVID-19
    Gianela M. Cancino-Castillo, Miguel A. Tresierra-Ayala, Jorge L. Campos-Reyna, Jaime Rosales-Rimache
    REVISTA MÉDICA VALLEJIANA/ Vallejian Medical Journal.2022; 11(2): 48.     CrossRef
  • Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq
    Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 33.     CrossRef
  • Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
    Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 159.     CrossRef
  • COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
    Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
    Diabetes Research and Clinical Practice.2021; 171: 108587.     CrossRef
  • A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
    Chia Siang Kow, Syed Shahzad Hasan
    Therapies.2021; 76(4): 361.     CrossRef
  • Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
    B. M. Bonora, A. Avogaro, G. P. Fadini
    Journal of Endocrinological Investigation.2021; 44(7): 1379.     CrossRef
  • Prognostic bioindicators in severe COVID-19 patients
    L. Bergantini, E. Bargagli, M. d'Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta
    Cytokine.2021; 141: 155455.     CrossRef
  • Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients
    Leila Moftakhar, Parisa Moftakhar, Elahe Piraee, Haleh Ghaem, Aliasghar Valipour, Habibollah Azarbakhsh
    International Journal of Diabetes in Developing Countries.2021; 41(3): 383.     CrossRef
  • DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
    André J. Scheen
    Diabetes & Metabolism.2021; 47(2): 101213.     CrossRef
  • Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
    Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurélie Carlier, Nicolas Chevalier, Christine Coffin‐Boutreux, Emmanuel Cosson, Anne Dorange, O
    Diabetes, Obesity and Metabolism.2021; 23(5): 1162.     CrossRef
  • Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
    Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882199648.     CrossRef
  • Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
    Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli
    Journal of Hypertension.2021; 39(4): 784.     CrossRef
  • Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis
    Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Qingrong Sun, Yue Zhang, Xiaosheng Wang
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
    Timotius Ivan Hariyanto, Andree Kurniawan
    Journal of Diabetes & Metabolic Disorders.2021; 20(1): 543.     CrossRef
  • Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
    Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
    Acta Diabetologica.2021; 58(8): 1101.     CrossRef
  • Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
    Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 777.     CrossRef
  • Post-infection depressive, anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19
    Flavia Ismael, João C.S. Bizario, Tatiane Battagin, Beatriz Zaramella, Fabio E. Leal, Julio Torales, Antonio Ventriglio, Megan E. Marziali, Silvia S. Martins, João M. Castaldelli-Maia
    Progress in Neuro-Psychopharmacology and Biological Psychiatry.2021; 111: 110341.     CrossRef
  • Managing diabetes in diabetic patients with COVID: where do we start from?
    Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
    Acta Diabetologica.2021; 58(11): 1441.     CrossRef
  • Is diabetes mellitus a wrongdoer to COVID-19 severity?
    Sanjib Sarkar, Dibyendu Das, Sawlang Borsingh Wann, Jatin Kalita, Prasenjit Manna
    Diabetes Research and Clinical Practice.2021; 178: 108936.     CrossRef
  • Dipeptidyl Peptidase 4 Inhibitor, an Update
    Ju Hee Lee
    The Journal of Korean Diabetes.2021; 22(2): 91.     CrossRef
  • Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19
    Zhenmu Jin, Mo Zheng, Jichan Shi, Xinchun Ye, Fang Cheng, Que-Lu Chen, Jianping Huang, Xian-Gao Jiang
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
    Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse, Tim Q. Duong
    Diabetes Care.2021; 44(7): 1564.     CrossRef
  • The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
    Wenxing Yang, Xuehong Sun, Jun Zhang, Kui Zhang
    Diabetes Research and Clinical Practice.2021; 178: 108977.     CrossRef
  • Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
    Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
    Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, Merve Elmaağaç, Oguzhan Sıtkı Dizdar, İlhami Çelik, Ali İhsan Günal
    Primary Care Diabetes.2021; 15(5): 806.     CrossRef
  • Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors
    Melina Farshbafnadi, Sara Kamali Zonouzi, Mohammadmahdi Sabahi, Mahsa Dolatshahi, Mohammad Hadi Aarabi
    Experimental Gerontology.2021; 154: 111507.     CrossRef
  • Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology
    Moudhi Almutlaq, Abir Abdullah Alamro, Fayhan Alroqi, Tlili Barhoumi
    CJC Open.2021; 3(8): 1060.     CrossRef
  • Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
    Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
    Marina Treskova-Schwarzbach, Laura Haas, Sarah Reda, Antonia Pilic, Anna Borodova, Kasra Karimi, Judith Koch, Teresa Nygren, Stefan Scholz, Viktoria Schönfeld, Sabine Vygen-Bonnet, Ole Wichmann, Thomas Harder
    BMC Medicine.2021;[Epub]     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
    Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 800.     CrossRef
  • Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
    Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
    E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
    Kardiologiia.2021; 61(9): 20.     CrossRef
  • Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
    Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
    Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545.     CrossRef
  • COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
    Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
    Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Decision Trees: Predictions of Global Vulnerability to Coronavirus Outbreaks
    Moacir José da Silva
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
    Liman Luo, Menglu Fu, Yuanyuan Li, Shuiqing Hu, Jinlan Luo, Zhihui Chen, Jing Yu, Wenhua Li, Ruolan Dong, Yan Yang, Ling Tu, Xizhen Xu
    Clinical Cardiology.2020; 43(12): 1478.     CrossRef
  • The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
    Antonia Anna Lukito, Raymond Pranata, Joshua Henrina, Michael Anthonius Lim, Sherly Lawrensia, Ketut Suastika
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2177.     CrossRef
  • Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data
    Seon-Rye Kim, Seoul-Hee Nam, Yu-Rin Kim
    International Journal of Environmental Research and Public Health.2020; 17(23): 8847.     CrossRef
  • Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
    Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko
    Endocrinology and Metabolism.2020; 35(4): 901.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer